KR830008686A - 비루스왁찐의 제조방법 - Google Patents

비루스왁찐의 제조방법 Download PDF

Info

Publication number
KR830008686A
KR830008686A KR1019820000136A KR820000136A KR830008686A KR 830008686 A KR830008686 A KR 830008686A KR 1019820000136 A KR1019820000136 A KR 1019820000136A KR 820000136 A KR820000136 A KR 820000136A KR 830008686 A KR830008686 A KR 830008686A
Authority
KR
South Korea
Prior art keywords
virus
sugar
gum
range
wax
Prior art date
Application number
KR1019820000136A
Other languages
English (en)
Other versions
KR870002161B1 (ko
Inventor
마사가즈 미하시
슌사꾸 고야마
Original Assignee
하아시바라 겡
가부시기 가이샤 하야시바라 세이부쓰 가가꾸 겡뀨우죠
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하아시바라 겡, 가부시기 가이샤 하야시바라 세이부쓰 가가꾸 겡뀨우죠 filed Critical 하아시바라 겡
Publication of KR830008686A publication Critical patent/KR830008686A/ko
Application granted granted Critical
Publication of KR870002161B1 publication Critical patent/KR870002161B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18834—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/805—Drug, bio-affecting and body treating compositions involving IgE or IgD
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/825—Bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

비루스 왁진의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 비루스와 당질과를 공유결합시켜서 생성하는 비루스 당질 결합물을 채취하는 것을 특징으로 하는 비루스 왁찐의 제조방법.
  2. 제1항에 있어서 당질이라 함은 전분, 아밀로오스, 덱스트란, 폴리슈크로오스, 풀루란, 엘시난, 커드란, 아라비아검, 트라기칸트검, 구아검, 크산틴검, 가라기난, 펙틴, 셀룰로오스, 글루코만난, 키토산 또는 이들의 다당류와 부분가스분해물 중에서 선택된 하나 또는 그 이상의 멤버인 청구범위 제1항의 비루스 왁찐의 제조방법.
  3. 제1항에 있어서 비루스라 함은 왁찌니아비루스, 폴리오비루스, 인푸렌자비루스, 일본뇌염비루스, 황열비루스, 마진비루스, 풍진비루스, 뭄푸스비루스, B형 간염비루스, 아데노비루스, EB비루스, 개디스텐인바비루스, 광견병비루스, 센다이비루스, 뉴캣슬병 비루스 등에서 선택된 하나 또는 그 이상의 멤버인 청구범위 제1항의 비루스 왁찐의 제조방법.
  4. 제1항에 있어서 당질의 평균분자량의 범위가 1,000-10,000,000인 청구범위 제1항의 비루스 왁찐의 제조방법.
  5. 제1항에 있어서 비루스 당질 결합물이라 함은 온도 약0-100℃, pH약 3-12에서 약 0.1-50시간 범위인 청구범위 제1항의 비루스 왁찐의 제조방법.
  6. 제1항에 있어서 비루스와 당질과의 중량비가 1:100-100:1범위인 청구범위 제1항의 비루스 왁찐의 제조방법.
  7. 제1항에 있어서 결합법이라 함은 디아조법, 알킬화법, 가교법, 펩프티법 또는 S-S결합법인 청구법위 제1항의 비루스 왁찐의 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR8200136A 1981-02-09 1982-01-14 비루스 왁진의 제조방법 KR870002161B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP81-17643 1981-02-09
JP56017643A JPS57136528A (en) 1981-02-09 1981-02-09 Preparation of viral vaccine

Publications (2)

Publication Number Publication Date
KR830008686A true KR830008686A (ko) 1983-12-14
KR870002161B1 KR870002161B1 (ko) 1987-12-14

Family

ID=11949534

Family Applications (1)

Application Number Title Priority Date Filing Date
KR8200136A KR870002161B1 (ko) 1981-02-09 1982-01-14 비루스 왁진의 제조방법

Country Status (7)

Country Link
US (1) US4659569A (ko)
JP (1) JPS57136528A (ko)
KR (1) KR870002161B1 (ko)
CH (1) CH650683A5 (ko)
FR (1) FR2499412B1 (ko)
GB (1) GB2095552B (ko)
IT (1) IT1154270B (ko)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
JPS6147186A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst インフルエンザウイルスの精製方法
JPS6147185A (ja) * 1984-08-09 1986-03-07 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスの精製方法
JPS6147187A (ja) * 1984-08-10 1986-03-07 Chemo Sero Therapeut Res Inst 狂犬病ウイルスの精製方法
JPH084508B2 (ja) * 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
EP0326111A3 (en) * 1988-01-29 1989-12-27 New York Blood Center, Inc. Peptide derivatives rendered immunogenic when administered with alum as an adjuvant
JP2896580B2 (ja) * 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
US5397568A (en) * 1989-10-02 1995-03-14 Whitfill; Craig E. Method of treating infectious bursal disease virus infections
BR9007702A (pt) 1989-10-02 1992-08-18 Embrex Inc Metodo de tratamento
JP3522772B2 (ja) * 1991-05-21 2004-04-26 台糖株式会社 ワクチンの免疫効果増強剤
US5194280A (en) * 1991-07-15 1993-03-16 F & Mp Research & Development Laboratories, Inc. Method of manufacturing a juice concentrate
US6607727B1 (en) * 1991-08-26 2003-08-19 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitus B virus
US6235288B1 (en) * 1992-08-26 2001-05-22 The Scripps Research Institute Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
GB9419979D0 (en) * 1994-10-04 1994-11-16 Medeva Holdings Bv Vaccine compositions
US6309671B1 (en) * 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
EP0914141A1 (en) * 1996-04-22 1999-05-12 Peter R. Rothschild Stabilized antihepatitis-b vaccine tablets
EP2316923B1 (en) * 1998-06-12 2017-10-18 Icahn School of Medicine at Mount Sinai Attenuated influenza viruses with altered interferon antagonist activity for use as vaccines and pharmaceuticals
WO1999064571A1 (en) * 1998-06-12 1999-12-16 Mount Sinai School Of Medicine Of The City University Of New York Interferon inducing genetically engineered attenuated viruses
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US8715940B2 (en) 1999-04-06 2014-05-06 Wisconsin Alumni Research Foundation Method of making recombinant influenza virus
US6896881B1 (en) * 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
WO2001077394A1 (en) * 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6524586B2 (en) * 2001-05-18 2003-02-25 Albany Medical College Enhancement of oligomeric viral immunogenicity
KR101229202B1 (ko) 2002-04-26 2013-02-01 메디뮨 엘엘씨 인플루엔자 바이러스의 생산을 위한 다중 플라스미드 시스템
US7465456B2 (en) 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
MX342639B (es) * 2003-05-28 2016-10-07 Wisconsin Alumni Res Found Virus de la influenza recombinantes de alta titulacion para vacunas y terapia genica.
CA2529647C (en) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
JP4771959B2 (ja) 2003-12-23 2011-09-14 メディミューン，エルエルシー インフルエンザウイルス作製のための多重プラスミド系
EP1771552B1 (en) * 2004-05-25 2012-08-01 MedImmune Vaccines, Inc. Influenza hemagglutinin and neuraminidase variants
CN1993140A (zh) 2004-06-01 2007-07-04 纽约大学西奈山医学院 遗传工程猪流感病毒及其应用
AU2005337178A1 (en) 2004-11-19 2007-04-19 Wisconsin Alumni Research Foundation Recombinant influenza vectors with tandem transcription units
WO2006088481A2 (en) * 2005-02-15 2006-08-24 Mount Sinai School Of Medicine Of New York University Genetically engineered equine influenza virus and uses thereof
EP2441471B1 (en) 2005-03-08 2014-10-08 MedImmune, LLC Reassortant influenza viruses
US20070111309A1 (en) * 2005-10-04 2007-05-17 Daelli Marcelo G Vero cell line adapted to grow in suspension
EP2010557B1 (en) 2006-03-31 2014-02-26 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses for vaccines
US7601356B2 (en) * 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
CN104278014A (zh) * 2006-08-09 2015-01-14 米迪缪尼有限公司 流感血凝素和神经氨酸酶变体
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
US8673613B2 (en) * 2007-06-18 2014-03-18 Medimmune, Llc Influenza B viruses having alterations in the hemaglutinin polypeptide
EP2227248B2 (en) * 2007-11-26 2018-01-31 GlaxoSmithKline Biologicals SA Adjuvanted glucans
ES2599908T3 (es) * 2007-11-26 2017-02-06 Glaxosmithkline Biologicals Sa Glucanos beta-1,3-enlazados conjugados
US9028463B2 (en) * 2008-06-30 2015-05-12 Hisamitsu Pharmaceutical Co., Inc. Microneedle device, and method for enhancing the efficacy of influenza vaccine by using microneedle device
EP2318043A4 (en) * 2008-07-11 2012-01-25 Medimmune Llc INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS
US8613935B2 (en) 2009-02-12 2013-12-24 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
ES2813347T3 (es) 2009-10-26 2021-03-23 Wisconsin Alumni Res Found Virus recombinantes de la influenza de alto título con replicación mejorada en células Vero
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
ES2556985T3 (es) 2011-01-11 2016-01-21 Capsugel Belgium Nv Nuevas cápsulas duras que comprenden pululano
CN102423304B (zh) * 2011-11-24 2013-03-13 黑龙江大学 N-2-羟丙基三甲基氯化铵壳聚糖/n,o-羧甲基壳聚糖新城疫减毒活疫苗纳米粒的制备方法
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EA201791907A1 (ru) 2015-02-26 2018-02-28 Бёрингер Ингельхайм Ветмедика Гмбх Бивалентная вакцина против вируса свиного гриппа
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
CN109477074B (zh) 2016-02-19 2023-01-24 威斯康星旧生研究基金会 用于疫苗开发的改进的乙型流感病毒复制
CA3059527A1 (en) 2017-04-14 2018-10-18 Capsugel Belgium Nv Pullulan capsules
BR112019021396A2 (pt) 2017-04-14 2020-04-28 Capsugel Belgium Nv processo para fabricação de pululano
US11241492B2 (en) 2019-01-23 2022-02-08 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to genes in influenza viruses
EP3921413A1 (en) 2019-02-08 2021-12-15 Wisconsin Alumni Research Foundation (WARF) Humanized cell line
WO2020223699A1 (en) 2019-05-01 2020-11-05 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1174854A (en) * 1967-07-07 1969-12-17 Miles Lab New Biologically Active Conjugates
US4003792A (en) * 1967-07-01 1977-01-18 Miles Laboratories, Inc. Conjugates of acid polysaccharides and complex organic substances
FR1604982A (en) * 1968-03-29 1972-06-26 Active protein product - with polymeric carrier
JPS5035325A (ko) * 1973-07-30 1975-04-04
JPS5639022A (en) * 1979-09-05 1981-04-14 Hayashibara Biochem Lab Inc Preparation of vaccine
JPS5823847B2 (ja) * 1981-02-06 1983-05-18 株式会社 林原生物化学研究所 抗ヒト蛋白質抗体の製造方法
JPS57136528A (en) * 1981-02-09 1982-08-23 Hayashibara Biochem Lab Inc Preparation of viral vaccine

Also Published As

Publication number Publication date
FR2499412B1 (fr) 1985-10-04
IT8247706A0 (it) 1982-02-02
JPS57136528A (en) 1982-08-23
GB2095552B (en) 1985-01-09
JPS6140211B2 (ko) 1986-09-08
GB2095552A (en) 1982-10-06
IT1154270B (it) 1987-01-21
CH650683A5 (fr) 1985-08-15
FR2499412A1 (fr) 1982-08-13
US4659569A (en) 1987-04-21
KR870002161B1 (ko) 1987-12-14

Similar Documents

Publication Publication Date Title
KR830008686A (ko) 비루스왁찐의 제조방법
KR920700557A (ko) 귀리의 용성 식이섬유 조성물
KR910011171A (ko) 과일재료처리법
KR890701699A (ko) 비비산성 입상염료
Mandal et al. Structure of the D-galactan isolated from Aloe barbadensis Miller
KR830006930A (ko) 열비가역성 겔화 시스템
KR950018048A (ko) 단백질과 그 제조 방법 및 용도
KR960028843A (ko) 김부각의 제조방법
DK152435C (da) Fremgangsmaade til fremstilling af polysaccharider eller polysaccharid-derivater ved polykondensation af glucose, maltose eller en blanding deraf med en i foedevarer acceptabel polycarboxylsyre-katalysator
IE781594L (en) Freeze-dried meningococcus polysaccharides
KR900003059A (ko) 무수 황화 나트륨 결정의 제조방법
FI853095L (fi) Foerfarande foer aotervinning av en gelbildande polysackarid, aotervunnen polysackarid och gel bildad daermed.
GB1357798A (en) Process for the separration of amyloses
Yamada et al. Characterization of a water-soluble glucan from Angelica acutiloba
KR910019530A (ko) 홍삼 제조방법
FR2431862A1 (fr) Produit alimentaire destine a la lutte contre le diabete
Anjaneyalu et al. An acidic xylan from the capsular polysaccharide-complex of Ocimum gratissimum seeds
KR830003212A (ko) 다당류 rbs 물질의 제조방법
KR900016295A (ko) 옥시메틸렌 공중합체의 제조방법.
KR870003728A (ko) 해초류를 이용한 조림식품의 제조방법
KR850000512A (ko) 다공형 특수 고열탄의 제조방법
KR860000022A (ko) 과일을 주재로 하는 스낵 과자의 제조방법
KR930000690A (ko) 아밀라제를 이용한 말토펜타오스(g5)의 제조방법
KR890009296A (ko) 수용성 식용 라면스프포장재
SU560990A1 (ru) Составна рабоча лопатка турбовентил тора